Novel prostate-specific promoter derived from PSA and PSMA enhancers

Molecular Therapy

Volumn 6, Issue 3, 2002, Pages 415-421

  Lee, Sang Jin ^a   Kim, Hong Sup ^a   Yu, Rong ^a   Lee, KangRyul ^a   Gardner, Thomas A ^a,b   Jung, Chaeyong ^a   Jeng, Meei Huey ^a,b   Yeung, Fan ^c   Cheng, Liang ^a   Kao, Chinghai ^a,b  

^a INDIANA UNIVERSITY   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Adenovirus; Gene therapy; Prostate; PSA; PSMA

Indexed keywords

ADENOVIRUS VECTOR; ANDROGEN; CHIMERIC PROTEIN; LUCIFERASE; PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN; TRANSCRIPTION FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CHIMERA; CONTROLLED STUDY; CYTOMEGALOVIRUS; DRUG EFFICACY; DRUG POTENCY; ENHANCER REGION; ENZYME ACTIVITY; EXPERIMENTAL ANIMAL; GENE ACTIVITY; GENE CONSTRUCT; GENE EXPRESSION; GENE THERAPY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; MOUSE; NONHUMAN; PROMOTER REGION; PROSTATE CANCER; REGULATORY MECHANISM; REPORTER GENE; TISSUE SPECIFICITY; TREATMENT PLANNING; VIRUS RECOMBINANT;

ADENOVIRIDAE; ANIMALIA; CUCUMBER MOSAIC VIRUS; CYTOMEGALOVIRUS;

EID: 0036764799     PISSN: 15250016     EISSN: None     Source Type: Journal    
DOI: 10.1006/mthe.2002.0682     Document Type: Article

References (21)

1. Greenlee, R. T., Hill-Harmon, M. B., and Murray, T. (2001). Cancer statistics. CA. Cancer J. Clin: 51: 15-36.
2. Cleutjens, K. B., et al. (1997). Both androgen receptor and glucocorticoid receptor are able to induce prostate-specific antigen expression, but differ in their growth-stimulating properties of LNCaP cells. Mol. Endocrinol. 11: 148-161.
3. Cleutjens, K. B., van Eekelen, C. C., van der Korput, H. A., Brinkmann, A. O., and Trapman, J. (1996). Two androgen response regions cooperate in steroid hormone regulated activity of the prostate-specific antigen promoter. J. Biol. Chem. 271: 6379-6388.
4. Schuur, E. R., et al. (1996). Prostate-specific antigen expression is regulated by an upstream enhancer. J. Biol. Chem. 271: 7043-7051.
5. Zhang, S., Murtha, P. E., and Young, C. Y. (1997). Defining a functional androgen responsive element in the 5′ far upstream flanking region of the prostate-specific antigen gene. Biochem. Biophys. Res. Commun. 231: 784-788.
6. Gotoh, A., et al. (1998). Development of prostate-specific antigen promoter-based gene therapy for androgen-independent human prostate cancer. J. Urol. 160: 220-229.
7. Wu, L., et al. (2001). Chimeric PSA enhancers exhibit augmented activity in prostate cancer gene therapy vectors. Gene Ther. 8: 1416-1426.
8. Horoszewicz, J. S., Kawinski, E., and Murphy, G. P. (1987). Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. Anticancer Res. 7: 927-935.
9. Pinto, J. T. (1996). Prostate-specific membrane antigen: a novel folate hydrolase in human prostatic carcinoma cells. Clin. Cancer Res. 2: 1445-1451.
10. Carter, R. E., Feldman, A. R., and Coyle, J. T. (1996). Prostate-specific membrane antigen is a hydrolase with substrate and pharmacologic characteristics of a neuropeptidase. Proc. Natl. Acad. Sci. USA 93: 749-753.
11. Xiao, Z., et al. (2001). Quantitation of serum prostate-specific membrane antigen by a novel protein biochip immunoassay discriminates benign from malignant prostate disease. Cancer Res. 61: 6029-6033.
12. Wright, G. L., Jr., et al. (1996). Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology 48: 326-334.
13. O'Keefe, D. S., et al. (1998). Mapping, genomic organization and promoter analysis of the human prostate-specific membrane antigen gene. Biochim. Biophys. Acta 1443: 113-127.
14. Watt, F., et al. (2001). A tissue-specific enhancer of the prostate-specific membrane antigen gene, FOLH1. Genomics 73: 243-254, doi:10.1006/geno.2000.6446.
15. Uchida, A., O'Keefe, D. S., Bacich, D. J., Molloy, P. L., and Heston, W. D. (2001). In vivo suicide gene therapy model using a newly discovered prostate-specific membrane antigen promoter/enhancer: a potential alternative approach to androgen deprivation therapy. Urology 58: 132-139.
16. Yeung, F., et al. (2000). Regions of prostate-specific antigen (PSA) promoter confer androgen-independent expression of PSA in prostate cancer cells. J. Biol. Chem. 275: 40846-40855.
17. Sharan, C, Hamilton, N. M., Parl, A. K., Singh, P. K., and Chaudhuri, G. (1999). Identification and characterization of a transcriptional silencer upstream of the human BRCA2 gene. Biochem. Biophys. Res. Commun. 265: 285-290.
18. Kallio, P. J., Poukka, H., Moilanen, A., Janne, O. A., and Palvimo, J. J. (1995). Androgen receptor-mediated transcriptional regulation in the absence of direct interaction with a specific DNA element. Mol. Endocrinol. 9: 1017-1028.
19. Matsubara, S., et al. (2001). A conditional replication-competent adenoviral vector, Ad-OC-E1a, to cotarget prostate cancer and bone stroma in an experimental model of androgen-independent prostate cancer bone metastasis. Cancer Res. 61: 6012-6019.
20. Rodriguez, R., et al. (1997). Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. Cancer Res. 57: 2559-2563.
21. Graham, F. L., and Prevec, L. (1995). Methods for construction of adenovirus vectors. Mol. Biotechnol. 3: 207-220.